Literature DB >> 33772115

CENP-A overexpression promotes distinct fates in human cells, depending on p53 status.

Daniel Jeffery1, Alberto Gatto1, Katrina Podsypanina1, Charlène Renaud-Pageot1, Rebeca Ponce Landete1, Lorraine Bonneville1, Marie Dumont2, Daniele Fachinetti2, Geneviève Almouzni3.   

Abstract

Tumour evolution is driven by both genetic and epigenetic changes. CENP-A, the centromeric histone H3 variant, is an epigenetic mark that directly perturbs genetic stability and chromatin when overexpressed. Although CENP-A overexpression is a common feature of many cancers, how this impacts cell fate and response to therapy remains unclear. Here, we established a tunable system of inducible and reversible CENP-A overexpression combined with a switch in p53 status in human cell lines. Through clonogenic survival assays, single-cell RNA-sequencing and cell trajectory analysis, we uncover the tumour suppressor p53 as a key determinant of how CENP-A impacts cell state, cell identity and therapeutic response. If p53 is functional, CENP-A overexpression promotes senescence and radiosensitivity. Surprisingly, when we inactivate p53, CENP-A overexpression instead promotes epithelial-mesenchymal transition, an essential process in mammalian development but also a precursor for tumour cell invasion and metastasis. Thus, we uncover an unanticipated function of CENP-A overexpression to promote cell fate reprogramming, with important implications for development and tumour evolution.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33772115      PMCID: PMC7997993          DOI: 10.1038/s42003-021-01941-5

Source DB:  PubMed          Journal:  Commun Biol        ISSN: 2399-3642


  106 in total

Review 1.  Interplay between the cancer genome and epigenome.

Authors:  Hui Shen; Peter W Laird
Journal:  Cell       Date:  2013-03-28       Impact factor: 41.582

2.  Expression and prognostic relevance of centromere protein A in primary osteosarcoma.

Authors:  Xiao-Min Gu; Jie Fu; Xiao-Jun Feng; Xue Huang; Shou-Mei Wang; Xin-Feng Chen; Ming-Hua Zhu; Shu-Hui Zhang
Journal:  Pathol Res Pract       Date:  2013-12-30       Impact factor: 3.250

Review 3.  Cellular Pliancy and the Multistep Process of Tumorigenesis.

Authors:  Alain Puisieux; Roxane M Pommier; Anne-Pierre Morel; Fabrice Lavial
Journal:  Cancer Cell       Date:  2018-02-12       Impact factor: 31.743

4.  Epithelial-mesenchymal crosstalk induces radioresistance in HNSCC cells.

Authors:  Teresa Bernadette Steinbichler; Abdelmoez Alshaimaa; Metzler Veronika Maria; Dejaco Daniel; Riechelmann Herbert; Dudas Jozsef; Skvortsova Ira-Ida
Journal:  Oncotarget       Date:  2017-12-14

Review 5.  New therapeutic strategies to treat human cancers expressing mutant p53 proteins.

Authors:  Giovanni Blandino; Silvia Di Agostino
Journal:  J Exp Clin Cancer Res       Date:  2018-02-15

Review 6.  The emerging links between chromosomal instability (CIN), metastasis, inflammation and tumour immunity.

Authors:  Andréa E Tijhuis; Sarah C Johnson; Sarah E McClelland
Journal:  Mol Cytogenet       Date:  2019-05-14       Impact factor: 2.009

7.  Asymmetric assembly of centromeres epigenetically regulates stem cell fate.

Authors:  Anna Ada Dattoli; Ben L Carty; Antje M Kochendoerfer; Conall Morgan; Annie E Walshe; Elaine M Dunleavy
Journal:  J Cell Biol       Date:  2020-04-06       Impact factor: 10.539

8.  The evolutionary history of 2,658 cancers.

Authors:  Moritz Gerstung; Clemency Jolly; Ignaty Leshchiner; Stefan C Dentro; Santiago Gonzalez; Daniel Rosebrock; Thomas J Mitchell; Yulia Rubanova; Pavana Anur; Kaixian Yu; Maxime Tarabichi; Amit Deshwar; Jeff Wintersinger; Kortine Kleinheinz; Ignacio Vázquez-García; Kerstin Haase; Lara Jerman; Subhajit Sengupta; Geoff Macintyre; Salem Malikic; Nilgun Donmez; Dimitri G Livitz; Marek Cmero; Jonas Demeulemeester; Steven Schumacher; Yu Fan; Xiaotong Yao; Juhee Lee; Matthias Schlesner; Paul C Boutros; David D Bowtell; Hongtu Zhu; Gad Getz; Marcin Imielinski; Rameen Beroukhim; S Cenk Sahinalp; Yuan Ji; Martin Peifer; Florian Markowetz; Ville Mustonen; Ke Yuan; Wenyi Wang; Quaid D Morris; Paul T Spellman; David C Wedge; Peter Van Loo
Journal:  Nature       Date:  2020-02-06       Impact factor: 49.962

Review 9.  Understanding aneuploidy in cancer through the lens of system inheritance, fuzzy inheritance and emergence of new genome systems.

Authors:  Christine J Ye; Sarah Regan; Guo Liu; Sarah Alemara; Henry H Heng
Journal:  Mol Cytogenet       Date:  2018-05-10       Impact factor: 2.009

Review 10.  Centromeric and ectopic assembly of CENP-A chromatin in health and cancer: old marks and new tracks.

Authors:  Abhishek Bharadwaj Sharma; Stefan Dimitrov; Ali Hamiche; Eric Van Dyck
Journal:  Nucleic Acids Res       Date:  2019-02-20       Impact factor: 16.971

View more
  6 in total

1.  Activation of homologous recombination in G1 preserves centromeric integrity.

Authors:  Duygu Yilmaz; Audrey Furst; Karen Meaburn; Aleksandra Lezaja; Yanlin Wen; Matthias Altmeyer; Bernardo Reina-San-Martin; Evi Soutoglou
Journal:  Nature       Date:  2021-12-01       Impact factor: 49.962

2.  FBXO38 Ubiquitin Ligase Controls Centromere Integrity via ZXDA/B Stability.

Authors:  Nikol Dibus; Vladimir Korinek; Lukas Cermak
Journal:  Front Cell Dev Biol       Date:  2022-06-23

Review 3.  Histone variants: The unsung guardians of the genome.

Authors:  Ernest O N Phillips; Akash Gunjan
Journal:  DNA Repair (Amst)       Date:  2022-02-17

Review 4.  Recent insights into mechanisms preventing ectopic centromere formation.

Authors:  Qianhua Dong; Jinpu Yang; Jinxin Gao; Fei Li
Journal:  Open Biol       Date:  2021-09-08       Impact factor: 6.411

Review 5.  CENP-A Regulation and Cancer.

Authors:  Charlène Renaud-Pageot; Jean-Pierre Quivy; Marina Lochhead; Geneviève Almouzni
Journal:  Front Cell Dev Biol       Date:  2022-06-02

6.  CENP-A is a potential prognostic biomarker and correlated with immune infiltration levels in glioma patients.

Authors:  Yuan Yang; Mengyun Duan; Yunfei Zha; Zijun Wu
Journal:  Front Genet       Date:  2022-08-29       Impact factor: 4.772

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.